Public Health Webinar Series on Blood Disorders

Public Health Webinar Series on Blood Disorders: Bringing Science Into Practice

CDC’s Division of Blood Disorders (DBD) is proud to offer its Public Health Webinar Series on Blood Disorders. The purpose of this series is to provide evidence-based information on new research, interventions, emerging issues of interest in blood disorders, as well as innovative approaches in collaborations and partnerships. We invite you to join us in this series.

Archives for 2022

Allison E. Burnett, PharmD, PhC, CACP

September 22, 2022

Presenter:
Allison E. Burnett, PharmD, PhC, CACP
President, Anticoagulation Forum
Antithrombosis Stewardship Pharmacist
University of New Mexico Hospital
Associate Adjunct Clinical Professor
University of New Mexico College of Pharmacy
Albuquerque, New Mexico

Caroline Cromwell, MD

Moderator:
Caroline Cromwell, MD

Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai
Medical Director, Thrombosis Services
Program, Mount Sinai Health System
New York, New York

Anticoagulation Stewardship: Optimizing Treatment for Venous Thromboembolism Across the Continuum of Care

In this webinar, Dr. Burnett defines anticoagulation stewardship and describes practice-level initiatives and national-level momentum behind these types of programs. She also discusses the role of pharmacists within the multidisciplinary team to promote anticoagulation stewardship for VTE patients throughout the continuum of care. Finally, she summarizes relevant clinical resources to aid clinicians in optimizing the care of VTE patients.


M.A. Bender, MD, PhD

June 2, 2022

Presenter:
M.A. Bender, MD, PhD
Director, Odessa Brown Comprehensive
Sickle Cell Clinic
Seattle Children’s Hospital
Seattle, Washington

Patrick Hopkins, BS

Presenter:
Patrick Hopkins, BS

Former Chief, Missouri State
Newborn Screening Laboratory
Chair, Association of Public
Health Laboratories’ (APHL)
Hemoglobinopathy Workgroup
Jefferson City, Missouri

Kathryn Hassell, MD

Moderator:
Kathryn Hassell, MD
Director, Hemoglobinopathies
Newborn Screening Follow-up
Program, Colorado and Wyoming
Director, Colorado Sickle Cell
Treatment and Research Center
University of Colorado Medicine
Aurora, Colorado

Newborn Screening for Thalassemia in the United States: Why, How, and What You Need to Know

Newborn screening is a state-based public health system that screens all newborn infants to identify congenital disorders with major impact before age five. These disorders may cause morbidity, disability, or death if not detected and treated promptly and appropriately.

In this webinar, Dr. Bender and Mr. Hopkins will review the clinical perspective as well as the basis for thalassemia newborn screening and discuss, with examples, how this is detected and quantified by screening methodologies used across the country. They will also review key points for interpreting thalassemia newborn screening results.


Aaron M. Wendelboe, PhD

March 24, 2022

Presenter:
Aaron M. Wendelboe, PhD
Edward E. and Helen T. Bartlett Chair in Public Health
Professor, Department of Biostatistics and Epidemiology
University of Oklahoma Health Sciences Center

Thomas Lee Ortel, MD, PhD

Presenter:
Thomas Lee Ortel, MD, PhD

Chief, Division of Hematology
Professor of Medicine and Pathology
Member of the Duke Cancer Institute
Duke University School of Medicine

Karon Abe, PhD

Moderator:
Karon Abe, PhD
Captain, US Public Health Service
Chief, Epidemiology & Surveillance
Branch Division of Blood Disorders
National Center on Birth Defects and Developmental Disabilities

Conducting Surveillance for Venous Thromboembolism Using Traditional and Novel Methods

In this webinar, Drs. Wendelboe and Ortel describe how novel methods, such as natural language processing, might be incorporated into surveillance systems for venous thromboembolism. This work is part of a larger collaborative project between the U.S. Centers for Disease Control and Prevention, the University of Oklahoma, and Duke University.

Archives for 2021

John Wood

November 18, 2021

Presenter:
John Wood, MD, PhD 
Director, Cardiovascular Magnetic Resonance Imaging
Professor of Pediatrics and Radiology at the Keck School of Medicine, University of Southern California
Los Angeles, California

Gregory Kurio

Moderator:
Gregory Kurio, MD
Associate Clinical Professor
Department of Pediatrics UCSF Benioff Children’s Hospitals
San Francisco, California

The Heart in Thalassemia

In this presentation, Dr. Wood discusses the three most common cardiovascular complications in thalassemia: myocardial iron overload, pulmonary hypertension, and accelerated cardiovascular aging. He will cover the biology of iron metabolism and its derangements by transfusion therapy, the monitoring of iron overload by MRI, and the prevention and treatment of iron cardiomyopathy. He also discusses the pathophysiology of pulmonary hypertension, the critical role of the spleen in preventing disease, screening for increased pulmonary artery pressures, and the management of established disease. Lastly, he examines the consequences of our successes in managing iron cardiomyopathy. The survival of thalassemia patients to middle age and beyond has revealed a phenotype of accelerated vascular aging, characterized by atrial arrhythmias and heart failure with preserved ejection fraction. Taken together, the cardiac complications in thalassemia represent a formidable clinical challenge; however, our improved understanding of the underlying pathophysiology provides insights in improved preventive measures.


Claire McLintock

October 12, 2021

Claire McLintock, MD, FRACP, FRCPA, ONZM (moderator)
National Women’s Health
Auckland City Hospital, Auckland, New Zealand

Alex C. Spyropoulos

Alex Spyropoulos, MD, FACP, FCCP, FRCPC
Northwell Health, New York City, New York

Alok A. Khorana

Alok A. Khorana, MD, FACP, FASCO
Cleveland Clinic, Cleveland, Ohio

Beverley Hunt

Prof. Beverley Hunt, MD, OBE
King’s College, London, England

Clotting Risks During Hospitalization: Exploring General Thromboprophylaxis and Special Cases

This webinar, co-hosted by the International Society on Thrombosis and Haemostasis and the Centers for Disease Control (Division of Blood Disorders), provides an overview on clotting risks during hospitalization.


Raj Kasthuri, MBBS

August 19, 2021

Raj Kasthuri, MBBS
Professor of Medicine, Division of Hematology
Director of the UNC Hereditary Hemorrhagic Telangiectasia Center of Excellence
Associate Director for Clinical Research,
UNC Blood Research Center
University of North Carolina at Chapel Hill

Hanny Al-Samkari, MD

Hanny Al-Samkari, MD
Assistant Professor of Medicine, Harvard Medical School
Classical Hematologist and Clinical Investigator,
Division of Hematology Oncology
Massachusetts General Hospital
Associate Director of the Massachusetts General Hospital Hereditary Hemorrhagic Telangiectasia Center of Excellence
Boston, Massachusetts

Hereditary Hemorrhagic Telangiectasia in 2021: Diagnosis and Advances in Treatment

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is an autosomal dominant bleeding disorder due to abnormal blood vessel formation affecting approximately 1 in 5,000 individuals. Diagnosis and management of HHT can be challenging and requires a multidisciplinary approach.

In this webinar, Dr. Kasthuri and Dr. Al-Samkari discuss various aspects of HHT including inheritance, clinical manifestations, approach to diagnosis, screening and management. The prevalence of anemia in the HHT population and challenges with its management that are unique to HHT will be emphasized, as will the emergence of systemic therapies to treat bleeding. In particular, systemic antiangiogenic treatments that are changing the treatment landscape of HHT will be highlighted. Additionally, the recently published Second International Guidelines for the Diagnosis and Treatment of HHT will be reviewed and discussed.


Dr. Alexis Thompson

June 24, 2021

Alexis A. Thompson, MD, MPH
Hematology Section Head
A. Watson and Sarah Armour Endowed Chair for Blood Diseases and Cancer

Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics, Northwestern University Feinberg School of Medicine

Associate Director for Equity and Minority Health
Robert H. Lurie Comprehensive Cancer Center and Northwestern University Feinberg School of Medicine

Bone Marrow Transplantation and Other Curative Approaches in Thalassemia

The thalassemia syndromes are a group of genetic blood disorders in which the production of one of the two different globin proteins (alpha or beta) that make up hemoglobin is reduced or absent. The result is anemia due to both ineffective erythropoiesis and chronic hemolysis, which typically begins in early childhood and lasts throughout life.

The clinical severity of thalassemia and interventions needed depend upon the globin chain affected and the type of genetic mutation. Persons with the most severe forms of thalassemia often require regular transfusions to treat the anemia and chelation therapy to prevent iron overload and associated sequelae. However, many patients with transfusion-dependent thalassemia (TDT) have struggled with adherence to the ongoing, intensive treatment regimen. Recent innovations, such as oral iron chelation agents, have helped improve adherence, and thus, prognoses (i.e., survival and quality of life in persons with TDT). Nonetheless, some patients and families are interested in definitive, potentially curative treatments.

In this webinar, Dr. Thompson describes considerations for stem cell transplantation, including patient characteristics, donor stem cell sources, and preparative regimens that impact clinical outcomes. She provides an overview of genomic therapies, such as gene addition and gene editing, and reviews the results of clinical studies on thalassemia.


Rachel P. Rosovsky, MD, MPH

March 11, 2021

Rachel P. Rosovsky, MD, MPH
Director, Thrombosis Research, Division of Hematology,
Massachusetts General Hospital

Assistant Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Multidisciplinary Care for Acute Pulmonary Embolism: The Pulmonary Embolism Response Team

Pulmonary embolism (PE) is a major cause of morbidity and mortality in the United States, accounting for up to 100,000 deaths annually. Although there has been a surge of new therapeutic tools and strategies designed to treat patients with PE, the outcomes for patients who present with massive or high-risk PE remain dismal.

In this webinar, Rachel Rosovsky, MD, discusses the model and purpose of pulmonary embolism response teams (PERT), presents the structure and organization, examines evidence for efficacy and usefulness, and shares the mission of the PERT Consortium. She also discusses future directions for research that will help evaluate the value of this innovative model and determine if this collaborative approach improves PE outcomes, improves clinical care, is cost effective, enriches patients’ quality of life, and advances the science of PE treatment.


Jean Grow, PhD

February 25, 2021 

Jean Grow, PhD
Professor of Advertising, Emeritus, and Co-Director of the Institute for Women’s Leadership
Marquette University
Milwaukee, Wisconsin

Nathan T. Connell, MD, MPH

Nathan T. Connell, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Associate Physician in the Hematology Division
Brigham and Women’s Hospital
Boston, Massachusetts

Angela Weyand, MD

Angela Weyand, MD
Assistant Professor of Pediatric Hematology and Oncology
University of Michigan
Ann Arbor, Michigan

Joint Guidelines on the Diagnosis and Management of von Willebrand Disease

The American Society of Hematology (ASH), International Society on Thrombosis and Hemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH) came together to develop updated clinical practice guidelines on the diagnosis and management of von Willebrand Disease (VWD). In this webinar, three of the guideline development panelists, Jean Grow, PhD, Nathan Connell, MD, MPH, and Angela Weyand, MD, present key recommendations from the guidelines, the process through which they were developed, and implications for the improved diagnosis and management of people with VWD.


For more information on the webinar series, please contact Cindy Sayers at cay1@cdc.gov.